Cargando…

New Approach to Chronic Back Pain Treatment: A Case Control Study

Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonetti, Matteo, Lauritano, Dorina, Ottaviani, Gian Maria, Fontana, Alessandro, Frigerio, Michele, Zambello, Alessio, Della Gatta, Luigi, Muto, Mario, Carinci, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855610/
https://www.ncbi.nlm.nih.gov/pubmed/36672581
http://dx.doi.org/10.3390/biomedicines11010073
_version_ 1784873420088934400
author Bonetti, Matteo
Lauritano, Dorina
Ottaviani, Gian Maria
Fontana, Alessandro
Frigerio, Michele
Zambello, Alessio
Della Gatta, Luigi
Muto, Mario
Carinci, Francesco
author_facet Bonetti, Matteo
Lauritano, Dorina
Ottaviani, Gian Maria
Fontana, Alessandro
Frigerio, Michele
Zambello, Alessio
Della Gatta, Luigi
Muto, Mario
Carinci, Francesco
author_sort Bonetti, Matteo
collection PubMed
description Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations in a short (one week), medium (three months) and long-term period (six months). Methods: We enrolled 246 patients (Group A) with low back pain treated with periradicular infiltrations of oxygen-ozone under CT guide combined with 800 mg/day of ALA + 600 mg/day of PEA + 200 mg/day of myrrh orally. Group B consisted of 176 patients with low back pain treated with periradicular infiltrations of steroids. Patients were clinically monitored one week after the end of treatment, at three months, and at six months using a modified version of McNab’s method. Results: In Group A, the one-week clinical follow-up registered a complete remission of painful symptoms in 206 patients (83.7%), and this manifestation remained optimal in 191 patients at the three-month follow-up (77.6%) and in 178 at six months (72.3%). While the results were satisfactory in 28 patients (10.9%) at one week, 32 (13%) in the medium term, and 41 (16.6%) in the long term, non-significant results were found in 12 patients in the control at one week (4.6%), in 23 at three months (9.3%) and in 27 at six months (10.9%). In Group B, at the short-term follow-up we obtained an excellent clinical result in 103 patients (80.5%), while at three months 85 patients reported the persistence of clinical benefit (66.4%) and at six months, 72 (56.2%) reported the same result. The result was rated satisfactory in 11 (8.5%) and poor in 4 (3%). At the three-month follow-up, 23 (18%) reported a satisfactory result, and 20 (15.6%) had a poor result. At six months, 24 (18.8%) reported the persistence of a satisfactory result while for 32 the result was poor (25%). Conclusion: The results highlight how the treatment associated with ozone therapy and oral administration of alpha-lipoic acid + palmitoylethanolamide and myrrh can be considered a valid alternative to common therapeutic approaches in the treatment of chronic low back pain.
format Online
Article
Text
id pubmed-9855610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98556102023-01-21 New Approach to Chronic Back Pain Treatment: A Case Control Study Bonetti, Matteo Lauritano, Dorina Ottaviani, Gian Maria Fontana, Alessandro Frigerio, Michele Zambello, Alessio Della Gatta, Luigi Muto, Mario Carinci, Francesco Biomedicines Article Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations in a short (one week), medium (three months) and long-term period (six months). Methods: We enrolled 246 patients (Group A) with low back pain treated with periradicular infiltrations of oxygen-ozone under CT guide combined with 800 mg/day of ALA + 600 mg/day of PEA + 200 mg/day of myrrh orally. Group B consisted of 176 patients with low back pain treated with periradicular infiltrations of steroids. Patients were clinically monitored one week after the end of treatment, at three months, and at six months using a modified version of McNab’s method. Results: In Group A, the one-week clinical follow-up registered a complete remission of painful symptoms in 206 patients (83.7%), and this manifestation remained optimal in 191 patients at the three-month follow-up (77.6%) and in 178 at six months (72.3%). While the results were satisfactory in 28 patients (10.9%) at one week, 32 (13%) in the medium term, and 41 (16.6%) in the long term, non-significant results were found in 12 patients in the control at one week (4.6%), in 23 at three months (9.3%) and in 27 at six months (10.9%). In Group B, at the short-term follow-up we obtained an excellent clinical result in 103 patients (80.5%), while at three months 85 patients reported the persistence of clinical benefit (66.4%) and at six months, 72 (56.2%) reported the same result. The result was rated satisfactory in 11 (8.5%) and poor in 4 (3%). At the three-month follow-up, 23 (18%) reported a satisfactory result, and 20 (15.6%) had a poor result. At six months, 24 (18.8%) reported the persistence of a satisfactory result while for 32 the result was poor (25%). Conclusion: The results highlight how the treatment associated with ozone therapy and oral administration of alpha-lipoic acid + palmitoylethanolamide and myrrh can be considered a valid alternative to common therapeutic approaches in the treatment of chronic low back pain. MDPI 2022-12-28 /pmc/articles/PMC9855610/ /pubmed/36672581 http://dx.doi.org/10.3390/biomedicines11010073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bonetti, Matteo
Lauritano, Dorina
Ottaviani, Gian Maria
Fontana, Alessandro
Frigerio, Michele
Zambello, Alessio
Della Gatta, Luigi
Muto, Mario
Carinci, Francesco
New Approach to Chronic Back Pain Treatment: A Case Control Study
title New Approach to Chronic Back Pain Treatment: A Case Control Study
title_full New Approach to Chronic Back Pain Treatment: A Case Control Study
title_fullStr New Approach to Chronic Back Pain Treatment: A Case Control Study
title_full_unstemmed New Approach to Chronic Back Pain Treatment: A Case Control Study
title_short New Approach to Chronic Back Pain Treatment: A Case Control Study
title_sort new approach to chronic back pain treatment: a case control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855610/
https://www.ncbi.nlm.nih.gov/pubmed/36672581
http://dx.doi.org/10.3390/biomedicines11010073
work_keys_str_mv AT bonettimatteo newapproachtochronicbackpaintreatmentacasecontrolstudy
AT lauritanodorina newapproachtochronicbackpaintreatmentacasecontrolstudy
AT ottavianigianmaria newapproachtochronicbackpaintreatmentacasecontrolstudy
AT fontanaalessandro newapproachtochronicbackpaintreatmentacasecontrolstudy
AT frigeriomichele newapproachtochronicbackpaintreatmentacasecontrolstudy
AT zambelloalessio newapproachtochronicbackpaintreatmentacasecontrolstudy
AT dellagattaluigi newapproachtochronicbackpaintreatmentacasecontrolstudy
AT mutomario newapproachtochronicbackpaintreatmentacasecontrolstudy
AT carincifrancesco newapproachtochronicbackpaintreatmentacasecontrolstudy